Osteosarcoma laboratory findings

	Osteosarcoma Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Osteosarcoma from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Staging
History and Symptoms
Physical Examination
Laboratory Findings
Biopsy
X Ray
CT
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Osteosarcoma laboratory findings On the Web
Most recent articles
cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Osteosarcoma laboratory findings All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Osteosarcoma laboratory findings
CDC on Osteosarcoma laboratory findings
Osteosarcoma laboratory findings in the news
Blogs on Osteosarcoma laboratory findings
Directions to Hospitals Treating Osteosarcoma
Risk calculators and risk factors for Osteosarcoma laboratory findings

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mohammadmain Rezazadehsaatlou[2].

Overview

Laboratory tests for osteosarcoma include complete blood count (CBC), serum alkaline phosphatase and lactate dehydrogenase.

Laboratory tests for osteosarcoma include the following:

Complete blood count (CBC), including differential
Platelet count
Liver function tests - Aspartate aminotransferase (AST), alanine aminotransferase (ALT), bilirubin, and albumin
Electrolyte levels - Sodium, potassium, chloride, bicarbonate, calcium, magnesium, phosphorus
Renal function tests - Blood urea nitrogen (BUN), creatinine
Urinalysis
Blood chemistry studies include:

↑ Kim HJ, Chalmers PN, Morris CD (February 2010). "Pediatric osteogenic sarcoma". Curr. Opin. Pediatr. 22 (1): 61–6. doi:10.1097/MOP.0b013e328334581f. PMID 19915470.
↑ Moore DD, Luu HH (2014). "Osteosarcoma". Cancer Treat. Res. 162: 65–92. doi:10.1007/978-3-319-07323-1_4. PMID 25070231.
↑ Ilaslan H, Schils J, Nageotte W, Lietman SA, Sundaram M (March 2010). "Clinical presentation and imaging of bone and soft-tissue sarcomas". Cleve Clin J Med. 77 Suppl 1: S2–7. doi:10.3949/ccjm.77.s1.01. PMID 20179183.
↑ Wu PK, Chen WM, Lee OK, Chen CF, Huang CK, Chen TH (November 2010). "The prognosis for patients with osteosarcoma who have received prior manipulative therapy". J Bone Joint Surg Br. 92 (11): 1580–5. doi:10.1302/0301-620X.92B11.24706. PMID 21037356.
↑ Obiedat H, Alrabadi N, Sultan E, Al Shatti M, Zihlif M (July 2018). "The effect of ERCC1 and ERCC2 gene polymorphysims on response to cisplatin based therapy in osteosarcoma patients". BMC Med. Genet. 19 (1): 112. doi:10.1186/s12881-018-0627-4. PMC 6035436. PMID 29980176.